DIRECT TO GOVERNMENT MARKETING
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

DIRECT TO GOVERNMENT MARKETING Trademark

Serial Number: 78623280

DIRECT TO GOVERNMENT MARKETING is a trademark filed by National Foundation of Science Biotechnology and Medical Research on May 4, 2005. The trademark is classified under Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

National Foundation of Science Biotechnology and Medical Research

215 East 68th Street, Suite 2N
New York, NY 10021

Entity Type: 99

Trademark Details

Filing Date

May 4, 2005

Registration Date

Not Registered

Goods & Services

Educational services, namely conducting conferences, meetings and seminars in the fields of healthcare, the healthcare industry and healthcare policy and distribution of course materials in connection therewith; educational and advocacy services, including providing policy and strategy recommendations in the field of healthcare in collegiate and graduate institutions; providing online educational information and resources in the fields of the healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, marketing, advertising, prescription practices, formulary design, pricing and reimbursement in pharmaceutical, biotechnology, medical device, medical insurance, hospital and pharmacy benefit industries

Electronic media, namely videos, DVDs, CDs and other prerecorded media in the field of healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, prescription practices, formulary design, pricing and reimbursement in pharmaceutical, biotechnology, medical device, medical insurance, hospital and pharmacy benefit industries

Publications, namely books, magazines, brochures, newsletters in the field of healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, prescription practices, formulary design, pricing and reimbursement in pharmaceutical, biotechnology, medical device, medical insurance, hospital and pharmacy benefit industries

Consulting services in the field of healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, prescription practices, formulary design, pricing and reimbursement ; promoting public awareness of the need for improving healthcare through the development of public and private-sector policy initiatives for improving the nature, quality, access to and delivery of healthcare; providing information and informational resources regarding the healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, marketing, advertising, prescription practices, formulary design, pricing and reimbursement in pharmaceutical, biotechnology, medical device, medical insurance, hospital and pharmacy benefit industries

Conducting research in the field of healthcare regarding the healthcare policy, economics, politics, access to and delivery of healthcare and pharmaceuticals, marketing, advertising, public relations, and issues which affect research, development, drug design, quality control, new drug approval, marketing, advertising, prescription practices, formulary design, pricing and reimbursement in pharmaceutical, biotechnology, medical device, medical insurance, hospital and pharmacy benefit industries

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jul 7, 2006 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 7, 2006 ABN2
NON-FINAL ACTION MAILED
Dec 9, 2005 CNRT
NON-FINAL ACTION WRITTEN
Dec 9, 2005 CNRT
ASSIGNED TO EXAMINER
Dec 1, 2005 DOCK
NEW APPLICATION ENTERED
May 12, 2005 NWAP